Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

HIPEC Elicits Similar Complication Rates, PFS in FIGO Stage III and IV Ovarian Cancer

March 1st 2024

HIPEC was not associated with additional complications or worse survival in patients with FIGO stage IV ovarian cancer vs those with stage III disease.

Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian Cancer

February 29th 2024

Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr DeBernardo on an Ovarian Cancer Patient Case Study

February 28th 2024

Robert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.

Outsmarting Chemo-Resistant Ovarian Cancer

February 28th 2024

Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer—its hunger for cholesterol.

Dr DeBernardo on the Use of Later-Line Maintenance Therapy in Ovarian Cancer

February 16th 2024

Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.

Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian Cancer

February 10th 2024

Susan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.

Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer

February 9th 2024

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.

HIPEC Plus Surgery Prolongs PFS and OS in Stage III Ovarian Cancer

February 8th 2024

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

Dr Smith on the Rationale for Investigating the Predictive Utility of CA-125 KELIM Score in Ovarian Cancer

February 6th 2024

Gabriella Smith, MD, discussed the predictive value of CA-125 KELIM score for survival outcomes with HIPEC during surgery in epithelial ovarian cancer.

FDA Grants Fast Track Designation to BNT325/DB-1305 for Platinum-Resistant Ovarian Cancer

February 5th 2024

FDA grants fast-track status to BNT325/DB-1305 for patients with platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian Cancer

February 2nd 2024

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer

January 31st 2024

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Dr Smith on the Predictive Value of CA-125 KELIM Score for Outcomes With HIPEC in Ovarian Cancer

January 26th 2024

Gabriella Smith, MD, discusses the predictive value of CA-125 KELIM score for outcomes with HIPEC during surgery in patients with epithelial ovarian cancer.

CA-125 KELIM Score May Predict Efficacy in Patients With Epithelial Ovarian Cancer Receiving HIPEC During Surgery

January 26th 2024

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.

Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.

Dr Crafton on the Impact of Mirvetuximab Soravtansine on Clinical Practice in Ovarian Cancer

January 25th 2024

Sarah Crafton, MD, discusses the integration of mirvetuximab soravtansine-gynx into clinical practice in the treatment of ovarian cancer.

Dr Miller on Updates With ADCs and Emerging Targets in Ovarian Cancer

January 24th 2024

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

Ongoing ADC Development Continues to Gain Traction in Ovarian Cancer

January 24th 2024

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

Dr Miller on the Impact of Mirvetuximab Soravtansine on Clinical Practice in Ovarian Cancer

January 23rd 2024

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.